Elexacaftor/Tezacaftor/Ivacaftor

Red

Brand Name(s):Kaftrio

Indication:Cystic Fibrosis with transmembrane conductance regulator (CFTR) mutations in adult and children <12 years who have >1 F508del mutation in CFTR gene

Rationale:1,2

Considered:Apr-21

Review Date:Jun-26

Comments:
NHS England has confirmed that ivacaftor, tezacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor will be made available as treatment options for people with cystic fibrosis who have one of an expanded range of CFTR mutations within the set criteria.

Elexacaftor/tezacaftor/ivacaftor is now licenced for patients aged <12 years years and above who have >1 F508del mutation in CFTR gene.